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Measures Main findings Study Weaknesses 
Acute effects of caffeine on 
attention: a comparison of 
non-consumers and 
withdrawn consumers 










Non-consumers were compared with 
withdrawn consumers over a 7-day washout 
period. Effects of withdrawal on the attention 
tasks were examined by carrying out 
performance testing on Day 2 of withdrawal. 
On day 8 a double-blind placebo-controlled 
caffeine challenge was carried out, with non-
consumers and consumers being randomly 
assigned to caffeine or placebo conditions. 
2 mg/kg single 
dose in 
decaffeinated 
coffee or tea. 
7 days 
Simple reaction time, 
focused attention 
task, categoric search 
task, repeated digits 
detection task 
Following 7 days withdrawal, ingestion 
of caffeine was associated with faster 
simple reaction time, fewer long 
responses, greater detection of targets 
in the cognitive vigilance task and 
faster encoding of new information in 
both non-consumers and withdrawn 
consumers, with no difference in 
effect size between them. 
Habitual consumers after 24 
hours of withdrawal performed 
worse than non-consumers on 
simple reaction time, number 
of targets detected and speed 
of encoding but there was not 
enough power to elicit a 
statistical significance. 
Effects of caffeine and 
caffeine withdrawal on 
mood and cognitive 
performance degraded by 







23 participants were provided with 
decaffeinated tea/coffee and 25participants 
with regular tea/coffee in the 3 weeks prior to 
testing; on the night before testing, 
participants’ sleep was restricted to 5 hours; a 
double blind placebo controlled caffeine 
challenge with cross-over on repeated testing 
2 days later. 




21 days for 50% 
of participants, 
overnight for 
the other 50% 
Simple reaction time, 
choice reaction time, 
the test of variables of 
attention. 
Overnight caffeine withdrawal was 
associated with negative cognitive 
effects. Caffeine ingestion had no 
positive cognitive effects. 
Of the participants who 
underwent 21 days of caffeine 
abstention, 50% were given 
caffeine and then re-tested on 
placebo 2 days later, meaning 
technically they could be in 
withdrawal. The authors felt 
the modest testing dose of 
caffeine would not affect their 
status as long term withdrawn. 
Effect of chronic caffeine 
intake on choice reaction 
time, mood, and visual 






Participants were divided into three 
randomized, balanced, blinded groups of 20 
subjects; on days 1–6 all participants 
consumed 3 mg/kg of caffeine; day 7-12 
groups were allocated to either placebo, 
3mg/kg or 6mg/kg caffeine. 
Placebo, 
3mg/kg or 
6mg/kg per day 
split in 2 divided 
dose capsules. 
5 days for 33.3% 
of participants 
Four choice reaction 
time test, scanning 
visual vigilance test. 
No difference between placebo and 
chronic (5 day) caffeinated states on 
tests of attention. 
Underpowered study. 
Caffeine improves reaction 
time, vigilance and logical 
reasoning during extended 
periods with restricted 
opportunities for sleep 




28.6 ± 4.7 
years 
50% receiving caffeine and 50% placebo during 
a 4 day period of caffeine abstention with 
sleep restricted to 4 hours a night 
800mg per day 
in 4 divided 
doses of 
chewing gum, 
for 4 days 







Sleep deprived participants receiving 
caffeine were significantly better on 
days 3,4 and 5 when tested overnight 
and early morning but not when 
tested during the day. 
The positive effects of caffeine 
being limited to nocturnal 




































































































































































































































































































      
Tea  
      
Hot  
Chocolate 
      
Cocoa  
      
Fizzy Drinks  
      
Other drinks  
      
Chocolate  
bar 
      
Over the counter 
medications 
        
Other  




























How many naps did you take during the day? 
 
Did you fall asleep: 




When sitting and talking to someone? 
 
When sitting after lunch? 
 
 
 (Circle answer) 
 Yes / No 
  
 Yes / No 
  
 Yes / No 
  
 Yes / No 
In total how many hours did you nap for during the 






QUESTION FOR PARTICIPANT WHEN THEY WAKE 
UP IN THE MORNING 
 
ANSWER 
What time did you go to sleep? 
   
What time did you wake up? 
   
How many times did you wake up in the night? 
   
What causes you to wake in the night? e.g. to go to 
the toilet, woke up with pain etc. 
   
Approximately how long did you stay awake during the 
night in total? 
   
Did you feel refreshed when you woke up this 













Did they say you snored in your sleep last night? 
 Yes / No 
Did they say you had pauses in your breathing last 
night? 
 
Yes / No 
Did they say you screamed/shouted in your sleep last 
night? 
 



















































70-79	 25.25	(4.11)	 27.78	(2.24)	 27.59	(2.04)	
80-89	 23.47	(2.97)	 25.08	(3.13)	 25.82	(2.75)	




















































25-29	 11.0	 2.3	 9.0	 2.5	 20.0	
30-34	 11.0	 2.5	 9.0	 2.8	 20.0	
35-44	 11.0	 2.5	 9.0	 2.8	 20.0	
45-54	 10.0	 2.5	 9.0	 2.5	 19.0	
55-64	 10.0	 2.8	 8.0	 2.5	 18.0	
65-69	 10.0	 2.5	 8.0	 2.5	 18.0	
70-74	 10.0	 2.5	 8.0	 2.3	 18.0	
75-79	 10.0	 2.5	 8.0	 2.0	 18.0	
80-84	 9.5	 2.3	 7.0	 2.0	 16.5	




























































































































































































































































































































































































































































































































































































































































































































Assessed for eligibility (n=19) 
Excluded (n=13) 
¨			Not meeting inclusion criteria (n=8) 
¨			Declined to participate (n= 4) 
¨			Unable to tolerate caffeine 
withdrawal (n=1) 
 
Lost to follow-up (n=0) 











































Assessed for eligibility (n=48) 
Excluded (n=28) 
¨			Not meeting inclusion criteria (n=0) 
¨			Declined to participate (n= 26) 
¨			Unable to tolerate caffeine 
withdrawal (n=2) 
 
Lost to follow-up (n=0) 
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Assessed for eligibility (n=78) 
Excluded (n=34) 
¨			Not meeting inclusion criteria (n=5) 
¨			Declined to participate (n= 26) 
¨			Unable to tolerate caffeine 
withdrawal (n=3) 
 
Lost to follow-up (n=0) 




Excluded from analysis (n=2 for non 
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Assessed for eligibility (n=89) 
Excluded (n=65) 
¨			Not meeting inclusion criteria (n=3) 
¨			Declined to participate (n= 62) 
¨			Unable to tolerate caffeine 
withdrawal (n=0) 
 
Lost to follow-up (n=0) 
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Assessed for eligibility (n=64) 
Excluded (n=52) 
¨			Not meeting inclusion criteria (n=7) 
¨			Declined to participate (n= 44) 
¨			Unable to tolerate caffeine 
withdrawal (n=1) 
 
Lost to follow-up (n=0) 
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6.3.6	Correlations	
A	Pearson	product-moment	correlation	coefficient	was	run	to	assess	the	
relationship	between	choice	reaction	time	and	MoCA	score.	There	was	a	moderate	
negative	correlation	between	choice	reaction	time	and	MoCA	score	r(11)	=	-0.64,	p	=	
0.04.	As	MoCA	score	increased,	cognitive	reactions	times	decreased	i.e.	were	faster.	
	
There	was	no	other	significant	correlation	between	age,	MoCA	score,	sex	or	habitual	
caffeine	intake	and	any	of	the	tests	described	above.	There	was	no	effect	of	
intervention	crossover	order	as	a	between	subjects	variable	for	any	of	the	tests.	
	
	
6.3.7	Sample	size	calculation	
From	the	small	sample	size	obtained	in	this	pilot	study,	I	have	calculated	the	
required	sample	size	to	power	a	definitive	study.	I	conducted	post	hoc	power	
analyses	using	G*Power	(Faul	et	al.,	2007)	with	power	(1	-	β)	set	at	0.80	and	α	=	
0.05,	two-tailed.		
	
To	test	our	hypotheses	with	statistical	significance	at	the	0.05	level:	
• alerting	attention	sample	sizes	would	be	N	=	198,	20	and	28	for	SRT,	CRT	and	
CogRT,	respectively		
• orienting	attention	sample	sizes	would	be	N	=	89		
• executive	attention	sample	sizes	would	be	N	=	2182,	74	and	219	for	
congruent,	incongruent	and	total	Stroop,	respectively		
• digit	span	sample	sizes	would	be	N	=	150,	66	and	43	for	forward,	backward	
and	total	digit	span,	respectively		
• WWT	sample	sizes	would	be	N	=	214	and	1,962,509	for	walking	and	WWT,	
respectively	
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6.4	Discussion	
6.4.1	Promising	results	
This	study	investigated	the	effect	of	caffeine	on	each	individual	subtype	of	
attention,	in	MS	participants.	As	a	pilot	study	the	main	aims	were	to	assess	
suitability	to	progress	to	a	larger	study,	including	determining	the	required	sample	
size	to	demonstrate	adequate	power	and	evaluating	recruitment	feasibility.	The	
sample	was	underpowered	for	hypothesis	testing	and	this	limits	the	interpretation	
of	inferential	statistics.	As	expected,	caffeine	did	not	significantly	improve	
performance	on	tasks	testing	any	attentional	network,	real	world	task	of	attention	
or	functional	tasks	of	working	memory,	although	trends	were	present.	Below	I	
discuss	the	feasibility	of	progressing	to	a	definitive	study	and	explore	the	trends	in	
data	analysis.	
	
The	low	recruitment	rate	despite	the	high	screening	numbers,	substantiate	
the	difficulty	in	recruiting	MS	patients	with	cognitive	problems	into	clinical	trials.	
Similarly	this	was	noted	in	Chapter	3	when	trying	to	recruit	dementia	with	Lewy	
body	participants.	Reassuringly	only	1	participant	was	unable	to	tolerate	caffeine	
withdrawal	and	was	therefore	withdrawn	from	the	trial,	prior	to	randomisation.	
This	represents	a	fallout	rate	of	8%	(1/13)	which	can	be	factored	into	future	sample	
size	calculations.	This	pilot	study	highlighted	the	principal	impediment	to	
recruitment	as	a	high	decline	rate	(44/64)	for	study	involvement.	Despite	
participants	being	recruited	from	a	research	database	they	were	still	reluctant	to	
participate.	Having	discussed	reasons	for	study	participation	decline	with	those	who	
were	screened,	it	is	clear	the	most	off	putting	features	of	the	study	relate	to	multiple	
attendances	(4	in	total)	and	difficulty	with	travel	arrangements.	The	MS	population	
is	younger	than	other	cohorts	in	this	thesis	and	are	often	actively	engaged	in	
employment.	Attendance	at	this	study	would	therefore	require	taking	4	days	annual	
leave	or	unpaid	leave,	which	is	clearly	unattractive	and	much	less	than	the	£10	per	
day	remuneration	fee	offered	with	the	trial.		
	
	 174	
	
The	alerting	attention	tests	all	show	a	non-statistically	significant	
improvement	with	caffeine;	the	choice	reaction	time	and	cognitive	reaction	time	
demonstrate	a	moderate	effect	size	according	to	Cohen	(Cohen,	1988).	As	expected	
there	is	no	suggestion	of	a	difference	in	simple	reaction	time	scores	as	this	does	not	
require	significant	cognitive	processing	and	hence	one	would	not	expect	caffeine	to	
attenuate	this	response.	The	post	hoc	power	analyses	suggest	the	non-significance	is	
due	to	the	study	being	underpowered,	as	would	be	expected	in	a	pilot	study.	If	a	
future	powered	study	demonstrated	significance	of	intervention	and	the	result	
effect	size	remained	the	same,	this	may	yield	a	significant	clinical	benefit	and	
improved	quality	of	life,	as	it	would	offer	a	treatment	for	impaired	attention	for	
which	no	medications	are	currently	licensed	or	recommended.		
	
Executive	attention,	measured	by	the	Stroop	task,	demonstrated	a	small	
effect	on	congruent	condition	but	a	much	larger,	moderate	effect	on	incongruent	
condition.	Once	again	the	post	hoc	power	analyses	suggested	inadequate	power	for	
significance	due	to	low	sample	size.	The	differential	between	the	effect	sizes	for	
congruent	and	incongruent	conditions	is	suggestive	of	caffeine	improving	executive	
attention.	In	the	Stroop	task	the	congruent	condition	represents	an	automatic	
response	and	acts	as	an	experiment	control	whilst	the	incongruent	condition	results	
represent	the	so	called	Stroop	interference	effect	(Lovett,	2005)	–	a	test	of	executive	
function.	An	attentional	enhancer	of	the	executive	domain	would	therefore	be	
expected	to	improve	the	incongruent	condition	in	preference	to	the	congruent	
condition,	as	is	the	case	in	this	pilot	study.		
	
Amantadine,	the	only	licenced	treatment	for	MS	fatigue	is	thought	to	mediate	
its	effects	as	a	dopamine	agonist,	it	is	unknown	whether	dopamine	pathway	
function	is	sub-clinically	low	in	MS	patients.	Caffeine	has	been	proposed	to	mediate	
its	alerting	effects	through	dopamine	up	regulation	(Brunye	et	al.,	2010).	Impaired	
executive	attention	will	produce	a	significant	burden	of	the	life	of	MS	suffers	who	
are	typically	young	as	it	can	result	in	occupation	loss	from	inability	to	complete	
complex	but	everyday	tasks	in	a	timely	manner.	A	future	study	would	be	to	solidify	
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the	extent	of	dopaminergic	activity	in	MS	suffers	and	if	this	was	established	as	low,	
future	trials	using	dopaminergic	medications	would	be	warranted.			
	
All	tests	were	assessed	for	correlations	to	age,	MoCA	score,	sex	and	habitual	
caffeine	intake.	The	rationale	being	to	tease	out	any	relationships,	which	would	
benefit	from	a	subgroup	analysis	or	could	be	re-targeted	in	a	future	study.	The	only	
significant	correlation	was	a	slower	Choice	Reaction	Time	score	with	decreasing	
Montreal	Cognitive	Score.	This	is	hardly	surprising	as	a	low	MoCA	score	indicates	
cognitive	decline,	a	significant	component	of	this	is	known	to	be	impaired	
processing	speed	and	therefore	one	would	expect	this	pattern	not	just	for	choice	
reaction	time	but	in	all	the	computerised	attention	tasks.	The	lack	of	other	
correlations	is	likely	an	indicator	of	inadequate	power.		
	
	 As	expected	there	was	no	significant	effect	or	trend	towards	caffeine	having	
an	effect	on	orienting	attention.	There	was	no	effect	or	trend	on	walking	while	
talking	time,	a	real	world	task	of	attention.	This	is	likely	due	to	the	task	not	being	an	
adequate	discriminator	as	a	result	of	its	relative	simplicity.	It	is	possible	that	a	more	
taxing	walking	while	talking	paradigm,	that	stresses	the	attentional	network,	would	
be	better	suited	to	probe	the	effects	of	caffeine.		
	
The	digit	span	served	as	a	test	of	working	memory,	whilst	again	not	
significant,	did	demonstrate	a	trend	towards	caffeine	having	a	negative	effect,	
reducing	forward,	backward	and	reliable	digit	span.	This	is	surprising	and	counter	
intuitive	to	the	notion	of	caffeine	improving	attention,	which	ought	to	improve	the	
functional	capacity	of	working	memory.	The	reason	for	this	is	not	clear	and	at	odds	
with	other	published	studies	examining	a	similar	effect	in	healthy	participants	
(Borota	et	al.,	2014,	Nehlig,	2010),	although	these	studies	did	not	fully	withdraw	
participants	prior	to	intervention.	A	possible	explanation	for	my	results	is	the	
association	of	anxiety	and	restlessness	induced	by	adrenergic	stimulation	by	
caffeine	ingestion	in	naïve	or	fully	withdrawn	individuals.	Caffeine	is	known	to	
induce	cerebral	vasoconstriction	(Field	et	al.,	2003)	and	it	may	divert	blood	flow	
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away	from	salient	cerebral	areas	involved	in	working	memory,	thus	reducing	its	
function.	It	is	therefore	advantageous	to	include	it	in	a	larger	trial	to	assess	whether	
attention	is	enhanced	at	the	expense	of	another	cognitive	domain.		
	
6.4.2	Limitations	
	 An	obvious	limitation	for	inferential	statistics	described	here	is	the	small	
sample	size	of	this	pilot	study.	The	poor	ratio	of	potential	participant	screened	to	
trial	participation	will	inevitably	result	in	participant	bias.	Participants	may	have	
been	more	inclined	to	participate	if	they	already	felt	they	received	a	cognitive	
benefit	from	caffeine	and	likewise	screened	participants	who	declined	might	have	
been	non	or	low	caffeine	consumers	who	derived	little	benefit	from	this	drug.		
	 It	would	have	been	useful	to	quantify	fatigue	in	participants	to	allow	
assessment	of	whether	subjective	scores	of	fatigue	correlated	with	impaired	
attention	and	if	response	to	caffeine	could	be	stratified	by	fatigue.	Obtaining	
baseline	and	post	treatment	fatigue	scores	is	a	feature,	which	can	be	built	into	to	
future	studies.		
	
	 The	walking	while	talking	task	appears	to	be	a	poor	discriminator	as	a	real	
world	task	of	attention.	Given	the	trend	of	improvement	following	caffeine	in	
alerting	and	orienting	attention,	one	would	expect	a	similar	trend	on	the	walking	
while	talking	task.	The	lack	of	improvement	could	be	due	to	a	genuine	lack	of	effect	
or	more	likely,	the	parameters	of	the	task	did	not	allow	an	effect	to	be	uncovered.	
The	walking	while	talking	task	was	too	easy	and	did	not	sufficiently	stress	
attentional	capacity	adequately,	therefore	participants	could	perform	the	task	
optimally	rendering	attentional	enhancers	redundant.		
		
6.4.3	Conclusion	
This	study	has	demonstrated	a	trend	toward	caffeine	having	a	beneficial	
effect	on	alerting	and	orienting	attention	as	expected	and	unexpectedly	worsening	
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working	memory.	The	pilot	study	provides	justification	for	a	larger	adequately	
powered	trial.		
	
I	would	propose	a	trial	of	80	participants	to	achieve	adequate	power	to	test	
the	hypothesis:	acute	caffeine	ingestion	will	improve	attention	in	the	alerting	and	
executive	domain	in	people	with	MS.	This	recruitment	target	takes	into	account	an	
expected	8%	drop	out.	
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Chapter	7	
General	Discussion	
	
The	experiments	described	in	this	thesis	were	designed	to	explore	the	
influence	of	caffeine	on	attention,	especially	with	respect	to	selective	attentional	
network	enhancement.	Over	the	years	several	attentional	models	have	been	
proposed	with	the	most	contemporary	being	Posner’s	trinity	of	attentional	
networks,	alerting,	orienting	and	executive,	integrating	both	neuroanatomical	
pathways	and	psychological	function	(Petersen	and	Posner,	2012).	The	therapeutic	
effects	of	caffeine	were	modelled	on	healthy	elderly	participants	and	cohorts	with	
impaired	attention	comprising	dementia	with	Lewy	bodies	(DLB),	Parkinson’s	
disease	(PD)	and	multiple	sclerosis	(MS).		The	remainder	of	this	chapter	will	précis	
key	concepts	identified	within	this	thesis,	describe	limitations,	suggest	future	
avenues	of	scientific	endeavour	and	draw	conclusions.	
	
	
7.1	Critical	flaws	in	the	existing	body	of	research	
	 There	is	over	a	hundred	years	of	research	investigating	the	effect	of	caffeine	
on	attention,	with	consensus	of	its	beneficial	psychostimulant	properties	purported	
by	recent	reviews	(Einother	and	Giesbrecht,	2013,	Nehlig,	2016).	This	is	countered	
by	a	minority	of	sceptics	(James,	2014,	Rogers	et	al.,	2013)	who	support	the	caffeine	
withdrawal	reverse	hypothesis.	This	asserts	caffeine	consumed	prior	to	full	
withdrawal,	simply	acts	to	ameliorate	the	fatiguing	effects	of	withdrawal	itself	
rather	than	produce	an	overall,	net	improvement	in	cognitive	function.		
Following	cessation,	caffeine	withdrawal	peaks	after	1	to	2	days	and	can	last	
up	to	9	days.	There	are	a	dearth	of	studies,	which	use	either	caffeine	naïve	or	fully	
withdrawn	participants	and	over	95%	of	all	studies	use	a	withdrawal	period	of	48	
hours	or	less,	leaving	their	validity	in	doubt.	Of	the	few	placebo	controlled	trials	
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assessing	the	effect	of	caffeine	on	attention	in	participants	who	had	been	withdrawn	
at	least	96	hours,	there	is	no	clear	improvement	in	attention	except	in	those	who	
were	sleep	deprived	(Kamimori	et	al.,	2015).	Studies	with	an	adequate	withdrawal	
period	were	performed	exclusively	in	healthy,	young	populations	and	did	not	
systematically	examine	if	attention	was	enhanced	by	caffeine	i.e.	of	the	trinity	of	
attentional	networks,	experimental	tasks	only	assessed	one	or	two	of	the	three	
attentional	domains.		
	 A	key	variable	when	performing	caffeine	research	is	determining	the	dose	of	
the	intervention.	Caffeine	doses	as	low	as	20mg	and	as	high	as	800mg/day	have	
been	trialled	but	few	studies	have	performed	head	to	head	comparisons	of	the	effect	
of	different	doses	on	the	same	cohort	using	the	same	attention	tests	(Lieberman	et	
al.,	1987,	Kamimori	et	al.,	2015).	It	is	perhaps	because	of	the	assumption	that	the	
greater	the	caffeine	dose,	the	greater	the	attentional	enhancement.		This	is	in	
juxtaposition	to	the	Yerkes-Dodson	law,	which	proposes	maximal	stimulation	is	not	
the	same	as	optimal	stimulation	(Yerkes	and	Dodson,	1908).	Instead	attention	
performance	conforms	to	an	inverted	U	shape	where	increases	in	arousal	are	
associated	with	an	increase	in	performance	up	to	an	optimum	point,	following	
which	higher	levels	of	arousal	only	impair	performance.	It	is	therefore	conceivable	a	
low	or	moderate	dose	may	be	more	effective	than	high	dose	caffeine.	
	
	
The	experiments	contained	within	this	thesis	are	novel	in	the	field	of	caffeine	
research	as	they	combined	(i)	a	battery	of	tests	systematically	developed	to	align	
with	each	of	the	three	attentional	network	domains;	(ii)	participants	whom	were	
fully	caffeine	withdrawn	prior	to	testing;	(iii)	novel	subject	groups	including	healthy	
elderly	and	those	with	medically	acquired	impaired	attention.	The	combination	of	
the	characteristics	described	above	ensured	robust	data	was	obtained	and	gave	
validity	to	interpretation	of	findings.		
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7.2	Caffeine	does	not	enhance	attention	in	healthy	elderly	
participants	
	 Healthy	elderly	participants	were	tested	on	tasks	assessing	attention	at	both	
habitual	caffeine	intake	levels	of	63mg	(i.e.	a	normal	coffee)	and	a	moderate	dose	of	
100mg	(Chapters	4,5	and	6).	In	both	cases	caffeine	failed	to	enhance	any	domain	of	
attention	when	compared	to	placebo.	This	is	in	stark	contrast	to	the	majority	of	
published	caffeine	trials	but	is	in	keeping	with	the	few	trials	that	employed	an	
adequate	caffeine	withdrawal	period	prior	to	testing.		
There	are	two	deductions	possible	from	this	finding.	Healthy	elderly	people	
by	definition	have	normal	attention,	for	their	age.	Therefore	according	to	the	
Yerkes-Dawson	law,	their	attention	is	not	amenable	to	therapeutic	enhancement	by	
caffeine	or	indeed	any	other	psychoactive	prescription	as	it	is	already	performing	
optimally.	Another	possibility	is	that	the	withdrawal	reversal	hypothesis	is	true.	
This	study	adds	to	the	small	body	of	research,	which	demonstrates	no	effect	of	
caffeine	on	attention	if	a	long	enough	withdrawal	period	is	utilised	prior	to	testing.		
The	only	way	to	delineate	between	the	two	deductions	was	to	test	the	effect	
of	caffeine	in	cohorts	of	participants	with	attention	deficits.	The	experiments	were	
therefore	repeated	in	participants	with	neurological	conditions,	which	
consequentially	impaired	their	attention.	
	
	
7.3	Caffeine	may	exert	its	main	effect	through	dopaminergic	
pathway	enhancement	
	 PD	participants	were	tested	using	the	same	experiment	design	as	for	healthy	
elderly	participants,	with	a	caffeine	dose	of	100mg	(Chapter	5).	Whilst	PD	is	
classically	considered	in	terms	of	its	motor	features,	cognitive	impairment	affecting	
attention,	memory	and	executive	function	are	increasingly	recognised,	(Adler	and	
Thorpy,	2005)	in	association	with	excessive	daytime	somnolence.	The	
pathophysiological	hallmark	of	PD	is	the	loss	of	dopaminergic	neurons	(Lee	and	
	 181	
	
Trojanowski,	2006).	Caffeine	is	proposed	to	elicit	an	effect	through	dopaminergic	
pathway	enhancement	via	inhibition	of	the	descending	GABAergic	system	or	
through	enhancement	of	the	ascending	brainstem	aminergic	system.	Adenosine	
receptors	are	co-localised	with	dopaminergic	D2	receptors	and	antagonise	their	
function	(Ferre	et	al.,	2008).	Caffeine	antagonises	adenosine	receptors	and	will	
consequentially	inhibit	the	somnolent	effect	of	adenosine	receptors	on	dopamine	D2	
receptor	pathways,	making	it	in	theory	an	ideal	wakefulness	promoting	medication.	
	 There	was	no	improvement	in	any	attentional	domain	in	PD	participants	
following	caffeine	ingestion.	A	possible	physiological	explanation	for	the	negative	
study	is	the	loss	of	dopamine	production	in	PD,	which	results	in	dopamine	receptors	
loss	rendering	the	co-localised	adenosine	receptors	redundant	and	the	effect	of	
caffeine	impotent.	
	 	
MS	participants	were	also	tested	on	attention	tasks	following	100mg	caffeine	
administration	as	part	of	a	pilot	study	(Chapter	6).	Fatigue	is	a	common	and	
debilitating	symptom	of	MS,	affecting	between	65	and	92%	(Branas	et	al.,	2000).	
The	pathophysiology	of	mental	fatigue	in	MS	has	not	been	elucidated	but	it	is	
increasingly	postulated	that	disruption	of	the	normal	hypothalamic-pituitary	axis	
and	neurotransmitter	pathways	are	the	underlying	basis	of	symptoms	(Bol	et	al.,	
2010,	Lucchinetti	et	al.,	2011,	Filippi	et	al.,	2002).		
Dopaminergic	networks	have	been	shown	to	be	involved	in	fatigue,	which	
has	been	proposed	to	occur	due	to	failure	of	the	non-motor	function	of	the	basal	
ganglia,	termed	the	dopamine	imbalance	theory	(Dobryakova	et	al.,	2015).	
Disruption	and/or	dysfunction	of	the	thalamo-striato-cortical	network	is	proposed	
as	the	anatomical	pathway	responsible	for	fatigue	resulting	in	neurotransmitter	
disruption	between	the	striatum	and	prefrontal	cortex	(Alexander	and	Crutcher,	
1990).	Dysfunction	of	the	thalamo-striato-cortical	pathways	correlates	with	
impairment	in	the	alerting	and	executive	attentional	networks.	Fatigue	is	poorly	
defined	but	is	in	part	a	subjective	manifestation	of	decreased	attention	and	was	
therefore	considered	amenable	to	attentional	enhancement.	
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	 As	a	pilot	study,	the	sample	size	was	underpowered	and	consequentially	did	
not	produce	any	significant	results,	however,	analysis	did	reveal	trends	within	the	
data.	Alerting	attention	as	assessed	by	the	cognitive	reaction	time	and	executive	
attention	assessed	by	the	Stroop	task,	both	demonstrated	non-significant	
improvement	following	caffeine	ingestion,	with	moderate	effect	size	according	to	
Cohen	(Cohen,	1992).	Whilst	this	data	should	be	interpreted	with	caution,	it	points	
towards	the	possibility	of	caffeine	enhancing	attention	in	cohorts	with	intrinsically	
impaired	attention	provided	they	have	intact	dopaminergic	pathways.	Of	course	a	
higher	powered	study	would	be	required	to	confirm	this	hypothesis.			
	
	
7.4	Selective	attentional	impairments	in	PD	participants	but	not	
DLB	participants	when	compared	to	healthy	aged	matched	controls	
Until	now	a	singular	study	has	not	systematically	assessed	each	domain	of	
attention	(or	equivalent	if	not	using	Posner’s	model)	in	PD	or	DLB	participants	with	
aged	matched	healthy	controls	for	comparison	(Chapters	3	and	5).	As	expected	DLB	
participants	performed	poorly	across	the	board	compared	to	controls.	By	contrast	
PD	participants,	who	had	cognitive	impairment	as	part	of	their	recruitment	criteria,	
demonstrated	selective	deficits	in	executive	and	to	a	lesser	degree	orienting	
attention.		
Interestingly	performance	of	PD	participants	in	a	real	world	task	of	attention,	
the	walking	while	talking	task,	demonstrated	no	difference	in	walking	time	but	a	
significant	difference	in	walking	while	talking	time,	a	surrogate	marker	of	falls	
(LaPointe	et	al.,	2010).	The	disparity	between	the	2	test	indices	suggest	motor	speed	
is	not	a	factor	of	the	significant	result,	instead	it	is	attributable,	at	least	in	part	to	
impaired	attention	in	PD.	Having	systematically	assessed	each	attentional	domain,	it	
can	be	deduced	impaired	walking	while	talking	time	corresponds	best	with	
impaired	executive	attention.	Phase	2	clinical	trials	have	demonstrated	promise	for	
Rivastigmine	as	a	remedy	for	gait	instability.	It	acts	as	a	cholinesterase	inhibitor,	
increasing	cholinergic	transmission	which	enhances	orienting	attention	(Henderson	
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et	al.,	2016).	My	data	confers	cholinesterase	inhibitors	may	be	of	some	benefit	at	
improving	gait	stability	but	optimising	dopaminergic	pathways	will	be	of	the	
greatest	benefit,	however,	this	may	not	be	feasible	in	this	population.	
	
	
7.5	Limitations	
	 The	optimal	caffeine	dose	to	enhance	attention	is	not	known.	I	opted	for	a	
moderate	dose	of	100mg	caffeine	as	the	intervention,	which	is	greater	than	found	in	
foodstuffs	but	smaller	than	any	other	trial,	which	fully	withdrew	participants	prior	
to	testing	(Smith	et	al.,	2013,	Rogers	et	al.,	2005,	Kamimori	et	al.,	2015,	Judelson	et	
al.,	2005).	Whilst	these	other	studies	exclusively	tested	healthy	participants,	my	
subject	groups	included	the	elderly	and	patient	groups.	I	therefore	adopted	a	more	
cautious	approach	due	to	the	increased	risk	of	side	effects.	It	could	be	argued	the	
caffeine	dose	used	was	simply	too	low,	however,	some	studies	have	shown	a	
beneficial	effect	from	caffeine	with	doses	as	low	as	20mg,	although	they	did	not	fully	
withdraw	their	participants	(Lieberman	et	al.,	1987).	Inter-individual	variability	in	
response	to	caffeine	is	recognised	but	difficult	quantify.	ADORA2A	genetic	
polymorphism	of	the	adenosine	receptor	is	recognised	as	significant	factor	in	
caffeine	sensitivity	(Cornelis	et	al.,	2007).	In	this	negative	trial	a	subgroup	analysis	
of	those	with	and	without	this	mutation	may	have	yielded	interesting	results.		
	
	 A	recurring	criticism	of	clinical	research	is	the	publication	of	underpowered	
data,	which	is	liable	to	type	I	error	(Carlisle	et	al.,	2015).	Where	appropriate	I	have	
included	a	post	hoc	sample	size	calculation.	Statistically,	it	would	be	most	
appropriate	to	present	the	study	power	result	but	comparing	the	required	sample	
size	for	a	powered	study,	to	the	actual	sample	size	is	an	easier	indicator	to	gauge.	
Clearly	a	greater	sample	size	would	have	produced	better	study	power,	more	
reliable	data	and	given	stronger	validity	to	deductions.	The	reality	of	clinical	
research	means	patient	research	databases	are	smaller	and	much	harder	to	recruit	
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from	than	healthy	participant	databases,	as	evidenced	by	the	recruitment	flow	
charts	in	each	data	chapter.	
	 The	use	of	research	registers	to	identify	potential	participants	and	the	
selective	nature	of	volunteering	to	participate	led	to	inherent	selection	bias.	As	this	
was	a	caffeine	study,	it	is	likely	participants	who	did	not	feel	any	beneficial	effect	
from	caffeine,	avoided	participation	and	this	is	reflected	to	a	degree	by	the	lack	of	
naïve	caffeine	consumer	participation.		
	
	 Attention	assessment	was	subdivided	according	to	Posner-Petersen	model	
and	an	established	and	validated	neuropsychological	test	was	chosen	to	test	each	of	
alerting,	orienting	and	executive	domains.	There	are	dozens	of	potential	tests	that	
could	be	used	to	assess	each	attentional	domain	with	my	final	choice	based	on	ease	
of	use	and	availability	as	a	customisable	computerised	test.	Posner’s	research	group	
have	developed	the	attentional	network	task	(Fan	et	al.,	2002)	which	is	a	singular	
computerised	test	designed	to	assess	all	attentional	domains.	I	did	not	use	this	as	
the	parameters	and	instructions	were	not	customisable	and	I	was	concerned	
participants	with	dementia	or	other	forms	of	cognitive	impairment	would	find	it	
difficult	to	understand	and	execute.	The	advantage	of	Posner’s	task	is	the	large	
frequency	of	trials,	which	can	be	performed	in	a	short	space	of	time.	Testing	fatigue	
is	always	a	concern	when	designing	an	experiment	and	collecting	as	much	data	as	
possible	only	serves	to	improve	analysis	reliability.		
	 It	is	important	to	recognise	the	limitations	of	the	Posner-Petersen	model	and	
consider	the	subsequent	effect	on	trial	design	and	result	interpretation.	The	
neuropsychological	tests	represent	assessment	of	more	than	a	singular,	unitary	
anatomical	pathway	as	alluded	to	by	Posner.	Had	I	chosen	a	different	attention	
model	by	Yu	and	Dayan	or	Corbetta	for	example,	the	neuropsychology	test	battery	
would	have	been	very	different	and	potentially	this	would	have	yielded	different	
results	with	a	different	conclusion.		
	
A	protocol	amendment	occurred	between	the	first	data	chapter	3	and	
subsequent	data	chapters	4,	5	and	6.	The	main	change	was	an	intervention	change	
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from	coffee	containing	63mg	of	caffeine	to	decaffeinated	coffee	with	the	addition	of	
100mg	crushed	caffeine	tablets.	With	the	change	in	intervention	came	a	change	in	
blinding	procedure,	moving	from	double	blind	to	single	blind.	This	reduces	the	
validity	of	the	study	as	the	investigator	running	the	experiment	now	knows	which	
intervention	the	participant	has	received	which	may	have	subconsciously	affected	
the	interaction	with	them.	The	cost	for	a	pharmacy	to	make	placebo	and	caffeine	
tablets	in	the	same	manner	was	not	possible	with	the	study	budget.	I	have	now	
discovered	empty	cellulose	capsules	are	available	for	purchase	from	an	online	
retailer;	these	cost	very	little	and	can	be	easily	made	into	batches	of	caffeine	and	
placebo,	and	subsequently	blinded	to	both	participant	and	researcher.	
	
	 During	the	caffeine	withdrawal	period	prior	to	intervention,	I	monitored	
caffeine	abstinence	by	a	daily	caffeine	consumption	survey.	At	least	some	
participants	completed	this	honestly	as	it	resulted	in	them	being	withdrawn	from	
the	trial.	The	ideal	monitoring	of	withdrawal	compliance	would	be	through	
measurement	of	caffeine	salivary	levels	(Smith	et	al.,	2013),	I	was	limited	from	using	
this	due	to	financial	constraints.	A	compromise	would	be	to	take	caffeine	saliva	
samples	but	not	process	them.	This	might	prompt	participants	to	ensure	they	
completed	caffeine	monitoring	honestly	and	has	been	adopted	as	a	strategy	by	other	
researchers	(personal	correspondence	with	Gary	Christopher).	
	 This	was	a	cross	over	trial,	which	fully	withdrew	participants	from	caffeine	at	
the	start	before	randomly	allocating	the	participant	to	caffeine	or	placebo	followed	
by	the	alternate	intervention	the	following	day.	Whilst	there	was	no	effect	of	
intervention	crossover	order	as	a	between	subjects	variable	for	any	of	the	tests,	it	is	
still	possible	participants	who	received	caffeine	first	(on	day	8)	followed	by	placebo	
(on	day	9)	may	have	been	in	a	state	of	withdrawal	during	the	second	day	of	testing.	
The	only	way	to	negate	this	was	to	space	testing	between	caffeine	and	placebo	by	
one	week,	extending	the	participant	caffeine	abstinence	period	to	15	days.	This	was	
thought	to	be	too	onerous	for	participants	and	had	the	potential	for	computerised	
test	practice	effects	to	be	lost	on	latter	testing	sessions,	causing	further	confounds	in	
the	data.	
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	 A	remit	of	this	research	was	to	objectively	assess	attention	and	the	effect	of	
caffeine	on	it	and	I	therefore	used	quantitative	neuropsychological	tests	and	
purposefully	avoided	subjective	measures	of	mood	or	attention.	Given	I	have	
negative	findings	it	would	have	been	interesting	to	assess	for	a	disparity	between	
subjective	feelings	of	improved	attention	with	objective	measures	of	attention.		
A	sleep	assessment	in	the	health	elderly	trial	would	allow	a	subgroup	analysis	to	
assess	if	sleep	duration/deprivation	correlated	with	response	to	caffeine.	Likewise	
in	the	MS	cohort	it	would	be	interesting	to	correlated	fatigue	scores	with	attention	
and	assess	if	they	are	differentially	enhanced	by	caffeine.	
Furthermore	I	have	proposed	caffeine	elicits	an	effect	through	dopaminergic	
pathway	enhancement	via	inhibition	of	the	descending	GABAergic	system	or	
through	enhancement	of	the	ascending	brainstem	aminergic	system.	Dopamine	is	
intimately	linked	to	reward	as	so	pre	and	post	caffeine	ingestion	mood	assessments	
would	potentially	add	weight	to	this	assertion.	These	assessments	are	brief	and	easy	
to	administer	in	any	future	studies.	It	would	have	been	useful	to	assess	for	
mesolimbic	symptoms	such	as	depression	or	anxiety	via	questionnaire	and	assess	
whether	this	correlated	to	caffeine	consumption.	A	negative	correlation	would	
support	the	hypothesis	of	caffeine	consumption	being	related	to	reward	
mechanisms.	Another	marker	of	dopamine	system	functioning	is	spontaneous	eye	
blink	rate.	This	has	been	shown	to	correlate	to	striatal	dopamine	levels	(Dreisbach	
et	al.,	2005)	and	is	clinically	observed	as	high	blink	rates	in	schizophrenics	and	low	
blink	rates	in	Parkinson’s	disease	(Swerdlow	et	al.,	2003).	I	could	have	taken	pre	
and	post	measures	of	eye	blink	rate	to	assess	if	dopaminergic	stimulation	was	a	
prominent	factor	in	performance.		
	
	
7.6	Future	directions	
There	may	be	a	role	for	caffeine	to	enhance	attention	in	health	elderly	
participants	when	they	are	sleep	deprived.	As	discussed	above	when	attention	is	
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optimal	as	is	typically	the	case	in	healthy	participants,	enhancement	is	likely	to	be	
futile.	However,	under	certain	environmental	conditions	that	stress	the	attentional	
system	of	healthy	people,	such	as	sleep	deprivation,	their	usually	optimal	attention	
will	become	sub-optimal	and	therefore	amenable	to	attentional	enhancers.		
	
	 The	pilot	study	involving	MS	participants	showed	great	promise	and	it	would	
be	interesting	to	repeat	this	experiment	as	a	powered	study,	although	recruitment	
in	this	population	is	difficult	and	may	require	a	multicentre	approach.	It	would	also	
be	worthwhile	investigating	the	effect	of	caffeine	in	patient	populations	with	intact	
dopaminergic	pathways	but	pathology	leading	to	impaired	attention	such	as	
Alzheimer’s	disease	and	certain	forms	of	acquired	brain	injury	for	instance	
encephalitis	and	traumatic	brain	injury.	These	conditions	lack	symptomatic	
treatments	and	setting	up	a	caffeine	study	would	be	safe,	supported	by	patient	
groups	and	financially	feasible.	
	
	 I	hypothesize	caffeine	elicits	its	main	effect	through	dopaminergic	
stimulation	and	this	may	relate	not	just	to	attention	enhancement	but	also	mood	
effects,	which	facilitate	tolerance	and	dependence.	Combining	neuropsychometry	
tests	of	attention	with	functional	MRI	imaging	would	allow	better	characterisation	
of	the	brain	areas	and	associated	neurotransmitter	networks	involved.		
	
	
7.7	Conclusions	
	 Within	this	thesis	I	have	judiciously	analysed	the	body	of	research	regarding	
the	effects	of	caffeine	on	attention.	Despite	a	critical	mass	of	papers	supporting	the	
beneficial	enhancing	effects	of	caffeine,	a	minority	of	authors	supported	the	caffeine	
withdrawal	reversal	hypothesis.	This	proposes	caffeine’s	attention	enhancing	effects	
are	the	result	of	reversing	caffeine	withdrawal,	caused	by	a	flawed	study	design	
with	an	inadequate	withdrawal	period	prior	to	testing.	The	few	caffeine	studies	with	
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an	adequate	withdrawal	period	have	exclusively	tested	young	healthy	participants	
and	have	not	demonstrated	a	clear	beneficial	effect.		
I	designed	an	experiment	to	test	whether	caffeine	improved	attention	in	
healthy	elderly,	DLB,	PD	and	MS	participants	following	a	full	caffeine	withdrawal	
period	prior	to	testing.	Attention	tests	were	matched	according	to	each	of	Posner’s	
trinity	of	attentional	domains,	alerting,	orienting	and	executive	attention.	In	
addition	I	included	the	walking	while	talking	task,	a	real	world	test	of	attention.	
Healthy	elderly	participants	did	not	have	their	attention	enhanced	by	
caffeine,	most	likely	because	their	attention	was	already	functioning	at	an	optimal	
level.		
Compared	to	age	matched	controls	DLB	participants	displayed	widespread	
deficits	in	attention	whilst	PD	participants	were	mainly	impaired	in	executive	
attention,	which	is	dependent	on	dopaminergic	network	function.	Neither	of	these	
participant	groups	had	their	attention	enhanced	by	caffeine	and	I	propose	this	is	
due	to	caffeine	eliciting	its	main	effect	through	dopamine	up	regulation.	In	both	
these	conditions	there	is	loss	of	dopaminergic	neurons,	dopamine	receptors	and	co-
localised	adenosine	receptors	and	therefore	endogenous	dopamine	enhancement	is	
not	possible,	preventing	caffeine	from	generating	an	attention	enhancing	effect.	
MS	participants	were	tested	as	part	of	a	pilot	study	and	demonstrated	
exciting	non-significant	data	trends.	There	was	a	moderate	effect	size	towards	an	
improvement	in	alerting	and	executive	attention.	These	non-significant	results	
should	be	viewed	with	caution	but	do	warrant	further	investigation	with	a	powered	
study.		
This	thesis	has	highlighted	the	misconception	of	caffeine	as	an	attention	
enhancer	for	healthy	individuals	and	given	weight	to	the	caffeine	withdrawal	
reversal	hypothesis.	Until	now	caffeine	has	not	been	trialled	as	an	acute	attention	
enhancer	in	populations	with	neurological	disease.	Whilst	the	results	are	negative	in	
conditions	with	dopaminergic	neuron	loss,	caffeine	shows	promise	as	an	enhancer	
in	conditions	with	impaired	attention	but	intact	dopamine	networks,	an	exciting	
avenue	for	future	research.		
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